QLG2198
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2024
QLG2198-301: Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
(clinicaltrials.gov)
- P3 | N=194 | Recruiting | Sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd.
New P3 trial • Dermatology • Pruritus • Renal Disease
1 to 1
Of
1
Go to page
1